Customize
Quick Links
Specialties

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Navigating Treatment Decisions in Pancreatic Cancer


Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based
 

Activity Overview

Despite treatment advances, pancreatic cancer is associated with a relatively poor outcome for most patients. A high level of integrated multidisciplinary cooperation can positively impact patient outcomes across the disease spectrum, from diagnosis to treatment and end-of-life care. In this Medical Crossfire® activity, moderated by Eileen M. O'Reilly, MD, you will engage with renowned surgical, radiation, and medical experts, Michael A. Choti, MD, Christopher Crane, MD, and George P. Kim, MD; gain insight into recommended treatment options and sequencing; consider the neoadjuvant, adjuvant, and surgical decision making necessary to manage patients with advanced pancreatic cancer; and compare the novel formulations of therapeutic options to inform treatment decisions.

For busy oncologists engaged in the daily management of complex patients with advanced pancreatic malignancies, this activity provides you with a multidisciplinary perspective to incorporate into the patient care setting.

Below are some clinical pearls and highlights from the activity:

  • Recent treatment advances have led to improvements in overall survival for some patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but significant effort is still needed to further develop screening and treatment modalities to improve long-term patient outcomes. 
  • Novel drug delivery formulations incorporating nanovectors, such as nab-paclitaxel and nanoliposomal irinotecan, play an important role in the treatment of advanced pancreatic adenocarcinoma. Enhanced understanding of the biology of PDAC will potentially lead to new treatment options directed against both the cancer cells and the surrounding microenvironment.
  • Close monitoring and management of toxicities is critical for patients with advanced PDAC because they may be at increased risk due to compromised performance status prior to treatment initiation.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, gastroenterologists, nutritionists, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment of pancreatic cancer. This activity will provide education to a broad multidisciplinary team who are invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Identify pharmacodynamic and pharmacokinetic properties of treatments for pancreatic cancer
  2. Evaluate clinical trial data regarding the efficacy of albumin-bound paclitaxel, liposomal irinotecan, and FOLFIRINOX in metastatic pancreatic cancer
  3. Place recent clinical trial findings in the context of evolving treatment paradigms in the field of advanced pancreatic cancer management
  4. Explain adverse events and approaches for the management of treatment-related toxicities across multiple lines of therapy in patients with pancreatic cancer
Moderator

Eileen M. O'Reilly, MD
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Professor of Medicine, Weill Cornell Medical College
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
New York, NY
 

DisclosuresGrant/Research Support: Agios, Array, AstraZeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche; Consultant: Agios, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, CARsgen, Celgene, Casi, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Vicus, Yakult

Faculty

Michael A. Choti, MD
Chief of Surgery
Banner MD Anderson Cancer Center
Phoenix, AZ
 
 

Disclosures: Dr. Michael Choti has no relevant financial relationships with commercial interests to disclose.

Christopher Crane, MD
Radiation Oncologist
Vice Chair, Department of Radiation Oncology
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Consultant: Celgene

George P. Kim, MD
Member, US Intergroup NCI Pancreas Cancer Task Force
Jacksonville, FL
 
 
 

DisclosuresConsultant: Celgene, Ipsen; Speaker’s Bureau: Celgene, Ipsen

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any of the companies that provided commercial support for this activity.

Related CME Activites
Related Articles






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By